Evaluation of rapid drug safety communication materials for patients in Japan.
Sign Up to like & getrecommendations! Published in 2021 at "Drug discoveries & therapeutics"
DOI: 10.5582/ddt.2021.01028
Abstract: Since 2011, pharmaceutical companies in Japan have been required to issue two types of documents regarding severe adverse drug reactions reported post-marketing, namely the Rapid Safety Communication Materials for Patients and the Related Materials. However,… read more here.
Keywords: communication; safety; drug; safety communication ... See more keywords